Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group.

ABSTRACT: Uncontrolled proliferation is a hallmark of cancer. In breast cancer, immunohistochemical assessment of the proportion of cells staining for the nuclear antigen Ki67 has become the most widely used method for comparing proliferation between tumor samples. Potential uses include prognosis, prediction of relative responsiveness or resistance to chemotherapy or endocrine therapy, estimation of residual risk in patients on standard therapy and as a dynamic biomarker of treatment efficacy in samples taken before, during, and after neoadjuvant therapy, particularly neoadjuvant endocrine therapy. Increasingly, Ki67 is measured in these scenarios for clinical research, including as a primary efficacy endpoint for clinical trials, and sometimes for clinical management. At present, the enormous vari

SUBMITTER: Dowsett M 

PROVIDER: S-EPMC3216967 | biostudies-literature | 2011 Nov

REPOSITORIES: biostudies-literature